# US 2016/0250326 A1 · Conjugates of GM-CSF and IL-7, and Compositions Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250326 A1
- Document ID: US20160250326A1
- Status: Published application
- Kind: A1
- Application number: 15/157,647
- Filed: 2016-05-18
- Published: 2016-09-01
- Earliest claimed: 2011-11-14
- Assignees: Emory University; Children's Healthcare of Atlanta, Inc.
- Applicants: Emory University; Children's Healthcare of Atlanta, Inc.
- Inventors: Jacques Galipeau; Hsiang-Chuan Hsieh
- Web page: https://patentgrep.com/patent/US20160250326A1

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 35/14: Blood; Artificial blood (perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42)
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61K 38/2046: {IL-7}
- A61K 39/0005: {Vertebrate antigens (from snakes A61K39/38)}
- A61K 39/001139: {Colony stimulating factors [CSF]}
- A61K 39/00114: {Interleukins [IL]}
- A61K 39/245: Herpetoviridae, e.g. herpes simplex virus
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/4233: {Colony stimulating factors [CSF]}
- A61K 40/4234: {Interleukins [IL]}
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- C07K 14/535: Granulocyte CSF; Granulocyte-macrophage CSF
- C07K 14/5418: {IL-7}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/55522: {Cytokines; Lymphokines; Interferons}
- A61K 2039/55527: {Interleukins}
- A61K 2039/572: {cytotoxic response}
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 2319/00: Fusion polypeptide
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

In certain embodiments, this disclosure relates to conjugates comprising GM-CSF and IL-7 and uses related thereto, e.g., enhancing the adaptive immune system. Typically the GM-CSF and IL-7 are connected by a polymer linker, e.g., polypeptide. In certain embodiments, the disclosure relates to nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such a nucleic acids.

## Claims

### Claim 1

A method of enhancing an immune response comprising administering a conjugate comprising a GM-CSF polypeptide and an IL-7 polypeptide having SEQ ID NO: 1 to a subject in need thereof.

### Claim 2 (depends on 2)

The method of claim 2, further comprising administering an antigen to the subject.

### Claim 3

A method of treating or preventing a viral infection comprising administering an effective amount of a pharmaceutical composition comprising a conjugate comprising a GM-CSF polypeptide and an IL-7 polypeptide having SEQ ID NO: 1 to a subject in need thereof, optionally in combination with an antigen and an adjuvant.

### Claim 4 (depends on 3)

The method of claim 3, comprising administration of an antigen.

### Claim 5

A method of treating or preventing a viral infection in a subject in need thereof comprising administering an effective amount of a vaccine in combination with a conjugate comprising a GM-CSF polypeptide and an IL-7 polypeptide having SEQ ID NO: 1 to the subject.
